J&J, Legend’s Carvykti quickly leaps ahead of BMS’ rival CAR-T – FiercePharma
- J&J, Legend’s Carvykti quickly leaps ahead of BMS’ rival CAR-T FiercePharma
- Bristol Myers’ Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer FiercePharma
- FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment BioSpace
- U.S. FDA approves expanded use of J&J’s cancer cell therapy Reuters
- Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma Business Wire
Read More: J&J, Legend’s Carvykti quickly leaps ahead of BMS’ rival CAR-T – FiercePharma